BioSpace News Archive

Brii Biosciences Limited, a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, announced new in vitro pseudoviris neutralization data demonstrating that its amubarvimab/romlusevimab combination therapy retains activity against the new Omicron SARS-CoV-2 variant.

Epizyme, Inc. presented updated safety and activity data from the Phase 1b portion of its Phase 1b/3 confirmatory study evaluating the investigational use of TAZVERIK®, a first-in-class, oral, selective inhibitor of EZH2, in combination with rituximab + lenalidomide in patients with relapsed/refractory follicular lymphoma who have been treated with at least one prior systemic therapy, including patients who are rituximab-refractory and/or POD24.

NexImmune, Inc. announced preliminary Phase 1/2 results from an ongoing study of NEXI-002, a patient-derived multi-antigen-specific CD8+ T cell treatment for patients with relapsed/refractory multiple myeloma who have failed ≥3 prior lines of therapy.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced longer-term results from the Phase 1b/2 CARTITUDE-1 study evaluating the efficacy and safety of ciltacabtagene autoleucel, an investigational B-cell maturation antigen -directed chimeric antigen receptor T-cell therapy administered as a single infusion, in the treatment of patients with relapsed and/or refractory multiple myeloma.

bluebird bio, Inc. announced updated results from its Phase 1/2 HGB-206 study of lovotibeglogene autotemcel gene therapy for sickle cell disease, including further analyses from its pivotal cohort, HGB-206 Group C, following enhancements to the manufacturing protocols and treatment process.

Editas Medicine, Inc., a leading genome editing company, reported in vitro and in vivo preclinical data on the enhanced tumor killing capacity of two modified induced pluripotent stem cell -derived natural killer cell therapies using Editas Medicine’s proprietary AsCas12a gene editing.

Innovent Biologics, Inc and IASO Biotherapeutics jointly announced the latest data from the phase 1/2 clinical study of a fully human B-cell maturation antigen chimeric antigen receptor T-cell therapy in an oral presentation at the 63rd American Society of Hematology Annual Meeting.

Seagen Inc. announced promising efficacy and safety results from Part B of an open-label, phase 2 clinical trial evaluating ADCETRIS® in a novel combination with nivolumab, doxorubicin, and dacarbazine as a frontline treatment for patients with advanced stage classical Hodgkin lymphoma.

Antengene Corporation Limited announced a clinical trial collaboration to evaluate the safety, pharmacokinetics and preliminary efficacy of ATG-017 in combination with Bristol Myers Squibb’s PD-1 checkpoint inhibitor, Opdivo®.

Avenue Therapeutics, Inc., a company focused on the development of intravenous tramadol for the U.S. market, announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $2.0 million, before deducting underwriting discounts and commissions and other estimated expenses payable by the Company.